DanfordCJTrivediHDBonderA. Bone health in patients with liver diseases. J Clin Densitom. 2020;23(2):212-222. doi:10.1016/j.jocd.2019.01.004.
2.
KostenuikPJNguyenHQMcCabeJ, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/ human) RANKL. J Bone Miner Res. 2009;24(2):182-195. doi:10.1359/jbmr.081112.
3.
MillerPD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis. 2014;64(2):290-304. doi:10.1053/j.ajkd.2013.12.018.
4.
BlockGABoneHGFangLLeeEPadhiD. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471-1479. doi:10.1002/jbmr.1613.
5.
Monge RafaelPMartin de FranciscoÁLFernández-FresnedoG. Denosumab and chronic kidney disease: severe life-threatening hypocalcemia. Nefrologia (Engl Ed). 2018;38(1):97-98. doi:10.1016/j.nefro.2017.01.004.
6.
SaekiCSaitoMOikawaT, et al. Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol. 2020;26(33):4960-4971. doi:10.3748/wjg.v26.i33.4960.
7.
PepeJColangeloLBiamonteFSonatoC, et al. Diagnosis and management of hypocalcemia. Endocrine. 2020;69:485-495. doi:10.1007/s12020-020-02324-2.
8.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154.
